bell
The current prices are delayed by 15 mins, login to check live prices.
Ipca Laboratories Ltd share price logo

Ipca Laboratories Ltd

(IPCALAB)

₹1582.50.78%

as on 04:01PM, 20 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals
F&O

Ipca Laboratories Ltd Analyst Rating

based on 19 analysts

BUY

60.00%

Buy

15.00%

Hold

25.00%

Sell

Based on 19 analysts offering long term price targets for Ipca Laboratories Ltd. An average target of ₹1564.37

Source: S&P Global Market Intelligence

Ipca Laboratories Ltd Share analysis

Ipca Laboratories Ltd price forecast by 19 analysts

Downside of-1.92%

High

₹1930

Target

₹1564.37

Low

₹900

Ipca Laboratories Ltd target price ₹1564.37, a slight downside of -1.92% compared to current price of ₹1582.5. According to 19 analysts rating.

Source: S&P Global Market Intelligence

Ipca Laboratories Ltd Performance

  • Day's Low

    Day's High

    ₹1,578
    Day's Price Range
    ₹1,616.4
  • 52 Week's Low

    52 Week's High

    ₹1,041
    52-Week Price Range
    ₹1,708.65
1 Month Return+ 1.36 %
3 Month Return+ 9.5 %
1 Year Return+ 49.85 %
Previous Close₹1,594.95
Open₹1,607.95
Volume6.83L
Upper Circuit-
Lower Circuit-
Market Cap₹38,390.52Cr

Ipca Laboratories Ltd Key Statistics

P/E Ratio61.18
PEG Ratio9.19
Market Cap₹38,390.52 Cr
P/B Ratio4.95
EPS20.86
Dividend Yield0.32
SectorPharmaceuticals
ROE9.81

Ipca Laboratories Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹38,390.52 Cr36.51%0.58₹529 Cr₹7,705 Cr
BUY₹14,100.35 Cr-2.24%0.52₹602 Cr₹2,851 Cr
BUY₹73,098.77 Cr33.6%0.56₹3,168 Cr₹29,001 Cr
HOLD₹98,565.65 Cr55.28%0.64₹3,854 Cr₹19,547 Cr
BUY₹59,732.90 Cr24.06%0.53NANA

About Ipca Laboratories Ltd

Ipca Laboratories is a fully integrated global pharmaceutical company, manufacturing and marketing over 350 formulations and 80 APIs in over 100 countries around the world. Established in 1949, with its original name as Indian Pharmaceutical Combine Association Limited, Ipca has 17 manufacturing units in India, producing APIs and Formulations that are approved by major drug regulatory authorities, including the US FDA, UK MHRA, South African MCC, Brazilian ANVISA and Australian TGA. Apart from native India, Ipca is also a recognized supplier of intermediates and APIs⁠—Atenolol, Chloroquine Phosphate, Furosemide, and Pyrantel Salts⁠—globally. Ipca has received accreditation from ISO 9001, Forbes Global 200 best small companies, WHOGMP, INVIMA Colombian, and German standards, making it a respected name in the pharmaceutical industry. Recently, Ipca has acquired a number of companies, namely Krebs Biochemicals and Industries Ltd., Pisgah Labs Inc., Trophic Wellness Private Ltd, Lyka Labs Limited, and M/s. Ramdev Chemical Private Limited, to further extend its presence in the global market.

Share Price: ₹1582.50 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹38,390.52Cr as of today
Revenue: ₹2,354.90Cr as on September 2024 (Q3 24)
Net Profit: ₹245.44Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: Premchand Godha
OrganisationIpca Laboratories Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Ipca Laboratories Ltd

  • IPCA Labs Sees Stake Sale Amid Stock Gains - 19 Dec, 2024

    IPCA Laboratories shares gained up to 6% despite a promoter selling 1.6% stake for ₹600 crore. The stock has risen 44% in 2024.
  • Ipca Laboratories Promoter Divests 1.6% Stake - 18 Dec, 2024

    Usha Madhukar Chandurkar, a promoter of Ipca Laboratories, divested a 1.6% stake for Rs 600 crore, decreasing promoter holdings from 46.3% to 44.7%. Following the sale, shares fell 2.68% to Rs 1,516.05.
  • Ipca Laboratories to Close Mexican Subsidiary - 04 Dec, 2024

    Ipca Laboratories has received approval to voluntarily close its wholly owned subsidiary in Mexico, which has not been operational for several years. This closure will not impact the company's overall business or financials.
  • Ipca Labs Reports Strong Q2 Sales Growth - 20 Nov, 2024

    Ipca Laboratories reported standalone net sales of Rs 1,810.94 crore for September 2024, marking an 8.92% year-on-year increase. The net profit for the period was Rs 244.12 crore, reflecting solid financial performance.

Insights on Ipca Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 2.05K Cr → 2.38K Cr (in ₹), with an average increase of 7.1% per quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 28.52% to 28.55% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 59.59 Cr → 229.48 Cr (in ₹), with an average increase of 42.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 135.8% return, outperforming this stock by 83.4%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 46.30% of holdings in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 57.1% return, outperforming this stock by 20.5%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 10.85% to 10.83% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 9.06% to 8.64% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, IPCALAB stock has moved down by -3.9%

Ipca Laboratories Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹2,033.96Cr (-)₹2,052.86Cr (↑0.93%)₹2,033.03Cr (↓0.97%)₹2,092.63Cr (↑2.93%)₹2,354.90Cr (↑12.53%)
Net Income₹137.44Cr (-)₹222.65Cr (↑62.00%)₹2.91Cr (↓98.69%)₹198.98Cr (↑6,737.80%)₹245.44Cr (↑23.35%)
Net Profit Margin6.76% (-)10.85% (↑60.50%)0.14% (↓98.71%)9.51% (↑6,692.86%)10.42% (↑9.57%)
Value in ₹ crore
Details2021202220232024
Total Assets₹6,098.57Cr (-)₹7,539.92Cr (↑23.63%)₹8,465.49Cr (↑12.28%)₹8,682.44Cr (↑2.56%)
Total Liabilities₹1,345.85Cr (-)₹2,064.16Cr (↑53.37%)₹2,588.19Cr (↑25.39%)₹2,333.73Cr (↓9.83%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹561.43Cr (-)₹1,096.06Cr (↑95.23%)₹831.72Cr (↓24.12%)₹762.29Cr (↓8.35%)₹830.51Cr (↑8.95%)

Index Inclusions

BSE Healthcare

₹44,095.46

-1.13 (-505.02%)

Nifty Midcap 150

₹21,050.60

-2.41 (-520.7%)

NIFTY PHARMA

₹22,501.85

-0.86 (-196.05%)

BSE 200

₹10,905.86

-1.89 (-210.17%)

BSE 500

₹35,082.25

-1.9 (-680.42%)

BSE Mid-Cap

₹46,226.50

-2.43 (-1152.75%)

S&P BSE 250 LargeMidCap

₹10,353.28

-1.89 (-199.23%)

Nifty 500

₹22,319.40

-1.9 (-432.75%)

S&P BSE 400 MidSmallCap

₹12,101.72

-2.24 (-276.79%)

Nifty Healthcare

₹14,474.90

-0.82 (-119.95%)

Nifty LargeMidcap 250

₹15,666.00

-2.09 (-334.75%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

S&P BSE 150 MidCap

₹15,862.89

-2.35 (-381.58%)

Nifty MidSmallcap 400

₹19,899.40

-2.27 (-461.95%)

Ipca Laboratories Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
46.3%
0.00
Foreign Institutions
10.83%
-0.20
Mutual Funds
28.55%
0.10
Retail Investors
8.64%
-4.64
Others
5.68%
7.89

Ipca Laboratories Ltd Key Indicators

Details20202021202220232024
Earning Per Share (₹)23.8945.2935.9119.3920.86
Details20202021202220232024
Return On Equity %19.1527.0616.828.919.81
Details20202021202220232024
Return On Assets %11.518.6911.735.576.3
Details20202021202220232024
Book Value Per Share (₹)143.07185.33215.41230.27249.59

Ipca Laboratories Ltd Valuation

Ipca Laboratories Ltd in the last 5 years

  • Overview

  • Trends

Lowest (18.72x)

October 10, 2019

Industry (56.23x)

December 19, 2024

Today (61.18x)

December 19, 2024

Highest (65.89x)

September 25, 2024

LowHigh

Ipca Laboratories Ltd Earnings and Dividends

  • Ipca Laboratories Ltd Earnings Results

    Ipca Laboratories Ltd’s net profit jumped 58.2% since last year same period to ₹229.48Cr in the Q2 2024-2025. On a quarterly growth basis, Ipca Laboratories Ltd has generated 19.37% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Ipca Laboratories Ltd Dividends November,2024

    In the quarter ending September 2024, Ipca Laboratories Ltd has declared dividend of ₹2 - translating a dividend yield of 0.25%.

    Read More about Dividends

Ipca Laboratories Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Ipca Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.

FAQs on Ipca Laboratories Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Ipca Laboratories Ltd shares.

Ipca Laboratories Ltd (IPCALAB) share price today is ₹1582.5

Ipca Laboratories Ltd is listed on NSE

Ipca Laboratories Ltd is listed on BSE

  • Today’s highest price of Ipca Laboratories Ltd is ₹1616.4.
  • Today’s lowest price of Ipca Laboratories Ltd is ₹1578.

PE Ratio of Ipca Laboratories Ltd is 61.18

PE ratio = Ipca Laboratories Ltd Market price per share / Ipca Laboratories Ltd Earnings per share

Today’s traded volume of Ipca Laboratories Ltd(IPCALAB) is 6.83L.

Today’s market capitalisation of Ipca Laboratories Ltd(IPCALAB) is ₹38390.52Cr.

Ipca Laboratories Ltd(IPCALABPrice
52 Week High
₹1708.65
52 Week Low
₹1041

Ipca Laboratories Ltd(IPCALAB) share price is ₹1582.5. It is down -7.38% from its 52 Week High price of ₹1708.65

Ipca Laboratories Ltd(IPCALAB) share price is ₹1582.5. It is up 52.02% from its 52 Week Low price of ₹1041

Ipca Laboratories Ltd(IPCALABReturns
1 Day Returns
-12.45%
1 Month Returns
1.36%
3 Month Returns
9.5%
1 Year Returns
49.85%